Author: Sutun Nayak

New Delhi [India], September 22: Viral respiratory infections (VRIs) have long been a persistent challenge for global healthcare. From seasonal flu-like illnesses to more severe viral conditions, these infections often affect millions each year, causing breathlessness, persistent cough, fatigue, and in many cases, long-term respiratory damage. Despite advances in modern medicine, treatment options remain limited, with many patients relying only on symptomatic relief. Unfortunately, overuse of antibiotics—despite their ineffectiveness against viruses—has worsened the crisis of antimicrobial resistance.

This growing medical gap called for a safe, evidence-based, and holistic approach. Rising to the challenge, Natural Solutions and Neutraceuticals Pvt Ltd (NSNPL) , a registered company in Mumbai, Maharashtra, developed Virulina®, a patent-awarded polyherbal formulation designed to combat VRIs with a unique triple action—immunomodulatory, anti-inflammatory, and antiviral properties in one formulation.

What makes Virulina® truly exceptional is not only its scientific validation—including

preclinical, toxicology, and clinical studies, and CSIR-backed antiviral research at the Regional Centre of Biotechnology, Faridabad—but also the passion and perseverance of its creators: Dr. Anil Kumar Sharma (BNYS, MD AM), Dr. Sandeep Arora (Ph.D., Pharmaceutical Sciences), and Dr. Dishya Sewda (BAMS).

The Motivation: A Patient-Centric Mission

The story of Virulina® is rooted in compassion and necessity. As Dr. Sharma recalls, patients suffering from viral respiratory complications often had no effective solutions. Families were helpless, physicians were constrained by limited treatment choices, and recovery was slow.

“We developed Virulina out of a sense of duty,” Dr. Sharma shares. “The suffering we saw inspired us to create something that could truly change outcomes. We had neither large financial reserves nor pharmaceutical backing—what we had was passion, knowledge, and the determination to serve patients.”

This motivation sparked a research journey that would blend traditional Ayurvedic wisdom with modern pharmacology, bridging two worlds to create a product capable of addressing an unmet global health need.

The Science Behind Virulina®

At its core, Virulina® is not just another herbal supplement—it is a scientifically validated phytopharmaceutical with a unique multi-target mechanism:

Immunomodulatory Action:
Virulina® enhances both innate and adaptive immune responses. It stimulates leukocyte migration, supports lymphocyte proliferation, and improves the phagocytic function of polymorphonuclear cells—helping the body respond effectively to viral invasions.

Anti-Inflammatory Properties:
In viral infections, hyperinflammation often causes more harm than the virus itself. Virulina® downregulates pro-inflammatory mediators such as nitric oxide, cytokines, chemokines, and growth factors. This mechanism helps reduce airway inflammation, prevent tissue damage, and maintain healthy respiratory function.

Antiviral Activity:
Perhaps most significantly, Virulina® interferes with viral RNA replication by targeting RNA polymerase—an enzyme crucial for viral survival. This reduces viral load and promotes faster recovery.

Mucolytic & Fibrinolytic Benefits:
Beyond its core triple action, Virulina® supports airway clearance, reduces mucus viscosity, and prevents clot-related complications, ensuring comprehensive respiratory care.

This integrative mechanism is what makes Virulina® stand apart from symptomatic treatments, offering a complete respiratory defense system.

Immunity, Infections & Sudden Cardiac Arrest

Emerging evidence highlights that immune modulation plays a vital role not only in fighting infections but also in maintaining heart health. While sudden cardiac arrest cannot be directly linked to any single factor such as vaccination, it is increasingly recognized that the after-effects of viral infections and immune challenges may influence cardiovascular function. By strengthening and balancing immune responses, formulations like Virulina® may contribute indirectly to resilience—not only against respiratory complications but also in supporting overall systemic health.

From Struggles to Recognition

The journey of Virulina® was not without obstacles. Conducting multi-stage research—preclinical, toxicology, clinical validation, and CSIR antiviral studies—required immense financial investment and scientific rigor.

“Collaborating pharmaceutical sciences with natural solutions is never easy,” Dr. Arora notes. “Each stage demanded resources we did not have. But our commitment kept us moving forward. Even when promoting the product and creating awareness posed new challenges, we did not stop.”

This perseverance, however, yielded remarkable recognition:

• Patent Award – Virulina® is the first herbal product awarded a patent in the category of viral respiratory infections.
• CSIR Virology Centre Study – Antiviral activity validated against Remdesivir, a known antiviral reference drug.
• AABI Torch Award (2024) – For Best Nomination (India), marking international recognition of innovation.
• Science & Technology Park, Pune – NSNPL was incubated and received equity investment from the Department of Science & Technology, Govt. of India, based on research quality.

Academic & Research Collaborations

To add further credibility, NSNPL collaborated with Amity Institute of Pharmacy, Mohali (Punjab) to create value out of traditional knowledge and validate Virulina®’s mechanism. Dr. Sandeep Arora, Professor & Dean, Faculty of Pharmaceutical Sciences, played an instrumental role as a co-researcher, bringing his academic expertise to strengthen the product’s scientific foundation.

Why Virulina® Matters in Today’s Healthcare

The significance of Virulina® extends beyond one product. It represents a paradigm shift in respiratory healthcare:

• Unmet Need: Few integrative solutions exist for viral respiratory infections beyond symptomatic care.
• Antibiotic Misuse: Antibiotics continue to be wrongly prescribed for viral illnesses, driving resistance.
• Chronic Sequelae: Many patients develop long-term respiratory complications after viral infections.
• Patient-Centric Demand: Increasingly, people seek safe, natural, and scientifically validated solutions.

Virulina® answers this demand by combining safety, efficacy, and evidence—offering both patients and physicians an integrative solution.

Looking Ahead: Global Goals

The NSNPL team has ambitious goals for Virulina®, envisioning it as a global benchmark in natural respiratory healthcare. Their objectives include:

• Preventive Role: Supporting immune preparedness to reduce infection risk.
• Therapeutic Role: Assisting in faster recovery during acute infections.
• Rehabilitation: Addressing persistent cough, airway hyperreactivity, and chronic lung issues.
• Safe Integrative Option: Providing physicians with an evidence-based herbal formulation that complements conventional care.
• Global Relevance: Expanding Virulina®’s reach internationally as a model phytopharmaceutical.

A Promise of Healing

Virulina® is more than a product—it is a promise of healing born from dedication, research, and compassion. It symbolizes how passion, science, and perseverance can overcome financial and institutional hurdles to create something of lasting value for humanity.

As Dr. Sharma concludes:

“Success is not just about recognition. It is about knowing that patients who once suffered without solutions now have hope. Virulina® is our contribution to global health.”

NSNPL, a DPIIT-recognised Innovative Startup, continues to focus on validated polyherbal solutions in the high infectious disease domain—helping communities overcome disease complications with safe, research-backed innovations.

To know more, visit: www.nsnpl2health.com

Disclaimer: This article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.

The healthcare sector in India as a whole was at the core of the healthcare sector as the country continued to celebrate its 10th Ayurveda Day, which marked ten years of notable growth in terms of integrating traditional medicine with the modern healthcare practice. The All India Institute of Ayurveda (AIIA) in Goa became the center of attention of this historic celebration as it presented some of the pioneering advances that make India one of the best providers of holistic medical services globally.

Ayurvedic medicine has been going through a transformative journey over the last ten years, and the Ministry of Ayush organised a press conference that was held in Panaji, Goa, to publicise the changes. The theme of this year, Ayurveda for People, Ayurveda for Planet, in a manner sums up the twofold emphasis on the health of the individual and the health of the environment that characterises contemporary Ayurvedic practice.

Revolutionary Healthcare Infrastructure Unveiled

Professor Pradeep Kumar Prajapati, Director of AIIA Goa, has declared the opening of the state-of-the-art medical facilities that will signify a quantum leap in integrative healthcare. The new Integrated Oncology Unit is a tribute to the growing contribution of Ayurveda in cancer therapies, the synergy of ancient medicine and the modern technology of medicine.

The Linen Processing Unit and the Central Sterile Supply Department show that AIIA Goa adheres to the global healthcare standards and, at the same time, does not sacrifice Ayurvedic treatment methods. Perhaps, most importantly, the new Blood Bank facility fills the gap between the old Ayurvedic culture and new emergency medical care, developing an entire healthcare ecosystem.

These infrastructural projects are an indication of the strategic vision of India to make Ayurveda a viable alternative to any form of conventional medicine, but in a manner that would guarantee their clients’ safety through the contemporary medical practice.

Global Recognition and Medical Tourism Expansion

AIIA Goa has developed into a 250-bed hospital that has 22 specialised outpatient departments, and it is taking care of more than 800 patients each day. The increasing international patient clientele that the institute has been receiving is a testament to the popularity of Ayurveda and the rise of India as a medical tourism destination.

Dean of AIIA Goa, Professor Sujata Kadam, highlighted that the Ayurveda Day celebration is not a mere ceremony as it is applied to be. This is a mark that illustrates our ten-year experience of wellness, equilibrium, and worldwide recognition, as she pointed out, that Ayurveda occupies a unique space in between tradition and science.

The partnership of AIIA Goa and the Goa Tourism Department has given a new dimension to the prospects of Medical Value Travel in getting international clients who want to take up original Ayurvedic therapies in a world-renowned medical center.

Evidence-Based Integration Strategy

The 10th Ayurveda Day festival highlighted that there is a very urgent need to integrate the old wisdom and the new ways of research. Professor Prajapati emphasized the importance of evidence-based methods, which would prove traditional treatment in the context of modern scientific models.

This integration approach overcomes the perennial distrust of conventional medicine by offering strict clinical verification but retaining the holistic values that characterise Ayurvedic practice. The strategy has won the goodwill of physicians, researchers, students, and policymakers across the country.

Sustainable Healthcare for Global Impact

The Ayurveda for People, Ayurveda for Planet is an indication of the holistic approach to the impact of healthcare on the environment. The focus of Ayurvedic medicine on natural solutions, green sourcing, and environmental harmony corresponds with the global sustainability objectives and provides good therapeutic results.

This green awareness makes the Indian traditional medicine system a potential answer to the sustainability challenge facing the pharmaceutical industry, to provide biodegradable remedies that have little impact on the environment.

National Movement Momentum

The Ayurveda Day, 10th celebration, has brought a nationwide movement across the traditional healthcare borders. The vision of the government to democratize access to good healthcare by the use of Ayurvedic medicine is shown in the call by Professor Prajapati that all stakeholders should be involved.

The movement also includes educational centers, research centers, health care facilities, and policy formulation organizations, which form an entire ecosystem in the development and modernization of Ayurvedic medicine.
The founding of the AIIA Goa in 2022 by the Prime Minister as a leading institution in Ayurvedic education, research, and healthcare is a sign that the government is willing to take traditional medicine to the next stage on the international level.

Future Implications

The Ayurveda Day celebration on the 10th marks the onset of a new era in Indian healthcare, where traditional wisdom and modern medicine meet to develop new methods of treatment. The effectiveness of the AIIA Goa integrated model is a blueprint of other similar institutions across the country, and this can transform the healthcare delivery system in India.

The blending of Ayurvedic concepts and contemporary medical facilities in India as the country goes on to establish itself as a global healthcare destination presents special competitive benefits in the global medical tourism marketplace.

The focus on the legacy of Lord Dhanvantari and the incorporation of the future possibilities in the celebration reflect the Indian interest in conserving the cultural values and welcoming scientific development as a means of developing holistic healthcare into a sustainable platform.

Mumbai (Maharashtra) [India], September 22: A miracle was recorded when a 78-year-old patient walked into HVS Symbiosis Super-Speciality Hospital, barely able to breathe.

His heart was pumping at just 25% of its capacity, his coronary arteries were critically blocked, and his mitral valve leaked so badly that every heartbeat was a struggle.

For most hospitals, the only option would have been high-risk open-heart surgery. For HVS, it was the start of a medical first.

Rethinking the Impossible 

“A patient like this is like balancing on a razor’s edge,” said Dr Ankur Phatarpekar.

“With such a weak heart, surgery itself could have triggered what we call afterload mismatch. Wherein, the heart collapses under sudden pressure changes. It’s a risk that often proves fatal.”

Instead of accepting the odds, the team designed a pioneering, two-step, minimally meddling plan, one that would give a shot at life.

First In-Human Trial: A Landmark Achievement 

Through a pinhole in the wrist, Dr Meghav Shah, Dr Amit Gangwani, Dr Aniruddha Pawar, Dr Harshad Sagar, Dr Kunal Patankar, Dr Gourish Shinde, Dr Kedar Pote, and Dr Pravin Lovhale performed a complex coronary angioplasty, carefully placing stents in two major arteries.

“The response was immediate,” noted Dr Meghav Shah. “We observed a measurable reduction in valve leakage, a clear indicator that the intervention was working as intended.”

Yet the fight wasn’t over. After 48 hours in the ICU, tests confirmed the mitral valve still leaked severely.

Led by the closing of the Leaky Valve without Surgery 

Then came the defining move: the MyCLIP TEER (Transcatheter Edge-to-Edge Repair). Instead of opening the chest, doctors reached the mitral valve through a vein in the leg.

“Picture a door that won’t close,” explained Dr Gangwani. “MyCLIP works like a precision hinge, which is a tiny, fabric-covered clip that brings the flaps together so the valve shuts again.”

With expert guidance from Dr Gourish Shinde and Dr Pravin Lovhale, the procedure sealed the leak. “The magic is in teamwork,” added Dr Shinde. As aptly put by Dr Kedar Pote, “It takes a perfect sync of imagers and interventionists to make such cutting-edge repairs succeed.”

Transition of ICU Monitors to Normal Breathing: 

It barely took time for the 78-year-old patient to be out of the ICU, breathing freely and resting without the bothersome fatigue that once defined his life.

“This isn’t just one success story,” emphasised Dr Harshad Sagar. “It’s proof of what’s possible when you refuse to accept limits.” 

“Two of these procedures were part of India’s First-in-Human studies, underlining HVS’s role as a frontrunner in advanced cardiac innovation.” – Dr Aniruddha Pawar

It signifies the future of Cardiac Care: 

“Once upon a time, a patient like this would have been considered inoperable,” reflected Dr. Kunal Patankar.

“Every heartbeat saved with MyCLIP is proof that the future is here.” 

About HVE & HVS

HVS Symbiosis Super-Speciality Hospital is a flagship member of the Heart & Vascular Superspeciality Group and is supported by the multi-disciplinary Heart Valve Experts (HVE). With HVE’s specialised team driving innovation in valve and structural heart care, HVS is redefining treatment for high-risk patients once considered beyond options. Powered by advanced technology, a cutting-edge cath lab, and some of India’s foremost interventional cardiologists, the hospital embodies HVE’s mission: transforming complex heart challenges into stories of renewed life.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.